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LEfSe	analysis	showed	that	the	genus	Roseburia	and	Faecalibacterium were enriched 
in	remission	pancolitis,	and	genera	Bilophila	and	Fusobacterium	were	enriched	in	active	
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1  |  INTRODUC TION
The	 intestinal	 tract	 houses	 a	 large	 and	 diverse	 community	 of	mi-







tion	 of	 the	microbiota	 (Danilova	 et	 al.,	 2019;	Nishida	 et	 al.,	 2017;	
Vemuri	et	 al.,	2017),	whereas	gut	dysbiosis	 along	with	 the	altered	
host	immune	response	has	been	observed	in	clinically	relevant	im-




in	 the	 so-	called	Montreal	 classification,	 defining	 the	 extent	 as	 E1	
indicates	ulcerative	proctitis;	E2	as	UC	on	 the	 left	 side;	and	E3	as	










been	 considered	 as	 a	 “fingerprint”	 reflecting	 the	 natural	 history	




bacteria	with	 pro-	inflammatory	 properties.	Microbiota	 diversity	 is	
also	reduced;	low	abundance	of	microorganisms	like	Firmicutes	and	
high	abundance	of	Proteobacteria	have	been	found	(Manichanh	et	al.,	
2012;	 Yu,	 2018).	 Rapid	 development	 and	 application	 of	 culture-	
independent,	high	throughput	DNA-	based	sequencing	technologies	
have	 elicited	 the	 recognition	 of	 such	 dysbiotic	 signatures,	 which	
may	play	a	role	during	the	early	identification	of	clinical-	therapeutic	
phases	 of	UC,	 and	particularly	 useful	 in	 severe	 clinical	manifesta-
tions	 like	 pancolitis	 (Peterson	 et	 al.,	 2008;	 Rintala	 et	 al.,	 2017).	
Despite	 this	 notion,	 the	 relation	 of	 gut	 dysbiosis	 with	 pancolitis	
has	been	poorly	characterized.	Given	the	increasing	UC	prevalence	
worldwide,	 including	 Latin	 American	 countries	 (Bosques-	Padilla	
et	al.,	2011;	Farrukh	&	Mayberry,	2014),	along	with	 the	strong	 in-





2.1  |  Study population
In	 this	 cross-	sectional	 study,	 groups	 of	 18	 patients	 with	 UC	 and	
clinical-	endoscopic-	evidenced	 pancolitis	 (active	 phase	 n	 =	 9	 and	
remission	phase	n	=	9)	as	well	as	15	healthy	participants,	attended	
the	 Department	 of	 Gastroenterology,	 Centro Médico Nacional ‘20 
de Noviembre’	 ISSSTE,	 Mexico	 City,	 Mexico,	 between	 July	 2017	






at	 remission	 phase	 of	 pancolitis	 received	 therapy	 based	 on	 phar-
macological	 treatment,	 a	 fiber-	rich	 diet,	 and	 the	 use	 of	 probiotics	
(Owczarek	et	al.,	2016).	Some	patients	with	active	pancolitis	did	not	
receive	treatment	due	to	non-	medical	 reasons,	 like	the	 inability	to	













K E Y W O R D S
active	and	remission	phase,	gut	dysbiosis,	gut	microbiota,	pancolitis
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<2	for	at	least	3	months	(Siegel	et	al.,	2018;	Van	Assche	et	al.,	2010).	




2.2  |  Stool samples
Stool	 samples	 were	 collected	 either	 during	 hospitalization	 (active	
pancolitis)	or	prepared	at	home	and	collected	during	programmed	
medical	 consultation	 (remission	 phase	 and	 healthy	 participants);	
samples	were	 stored	at	home	between	4	 and	8°C	 for	up	 to	24	h,	
before	hospital	collection.	Samples	were	collected	with	the	help	of	
a	stool	sampling	kit,	which	consisted	of	a	plastic	lining	to	cover	the	
toilet,	 two	 stool	 sample	 tubes	with	 spoons,	 two	 plastic	 bags,	 and	




2.3  |  DNA extraction of fecal samples
Frozen	stool	samples	were	thawed	on	ice,	and	approximately	200	mg	
were	added	to	dry-	bead	tubes	with	lysis	buffer	(AllPrep	PowerFecal	
DNA,	Qiagen).	 The	 stool	 samples	were	 homogenized	 followed	 by	

















overhanging	 adapters	 (Forward:	 AATGATA	 CGGC	 GACC	 ACCGA	
GATCT	ACAC),	(Reverse:	GGA	CTA	CHV	GGG	TWT	CTA	AT)	for	an-















beads	 and	 eluted	 in	 40	μL	 final	 volume.	 For	 the	 second	 step,	 a	 4	
μL	of	the	obtained	DNA	was	mixed	with	primers	PE-	PCR-	III-	F	and	
PE-	PCR-	IV-	barcode,	 in	 a	 25	 μL	 final	 volume	 PCR	 reaction	 (quad-
ruplicates),	at	run	cycle	conditions	of	98°C	for	30	s	[98°C	for	30	s,	
83°C	 for	 30	 s,	 72°C	 for	 30	 s]	 for	 7	 cycles,	 4°C	 hold.	 Then,	 the	 4	
PCR	reactions	were	pooled	and	the	products	were	cleaned	by	using	
16S Metagenomic Sequencing Purification	 beads	 (Caporaso	 et	 al.,	
2012).	 The	 DNA	 library	 concentrations	 were	 quantified	 and	 then	
multiplexed	 to	 provide	 the	 same	 amount	 of	DNA	 in	 each	 sample.	
A	single	 Illumina MiSeq	 lane	set	for	paired-	end	300-	basepair	reads	












2.6  |  Bioinformatic analysis
The	Illumina	Real-	Time	Analysis	software	(version	1.17.28)	was	used	





were	 entered	 in	 fastq	 format	 by	 using	 the	 split_libraries_fastq.
py	pipelines.	Sequences	 that	had	quality	value	 (QV)	scores	of	≥20	
(Phred	score	of	20)	for	no-	less	than	99%	of	the	sequence	were	se-
lected	 for	 further	 study.	All	 sequences	with	 ambiguous	 base	 calls	
were	 discarded.	 Subsequently,	 the	 sequences	 were	 grouped	 in	
Operational	Taxonomic	Units	 (OTU),	where	 the	pick_closed_refer-
ence_otus.py	 pipelines	 were	 used.	 QIIME,	 which	 uses	 the	 BIOM	
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format,	 was	 used	 to	 represent	 OTU	 tables	 (Bolyen	 et	 al.,	 2018;	
Dubinsky	&	Braun,	2015;	Edgar	et	al.,	2011).	Analyses	of	sequence	
reads	 were	 performed	 by	 using	 SILVA	multiclassifier	 tools	 with	 a	
97%	confidence	threshold	(Navas-	Molina	et	al.,	2013).	Subsequent	
analyses	of	diversity	index	were	all	performed	based	on	this	output	
normalized	 data	 (Allali	 et	 al.,	 2017;	 Aßhauer	 et	 al.,	 2015).	 To	 per-
form	the	diversity	analyses,	the	core_diversity_analyses.py	pipelines	
were	executed	with	the	pipeline	alpha_diversity.py.	Alpha	diversity	
metrics	 were	 calculated	 with	 QIIME,	 that	 is,	 the	 observed	 OTUs	
(observed	species)	and	the	phylogenetic	diversity	or	complete	tree	
PD	 (PD_whole_tree)	 (Bolyen	 et	 al.,	 2018);	 whereas	 the	 weighted	
distances	 of	 UniFrac	 of	 the	 beta	 diversity	 were	 determined	 with	
beta_diversity.py	pipelines,	and	the	R	software	v.2.15.3	was	used	to	
display	the	results	(Barwell	et	al.,	2015;	Chao	et	al.,	2006;	Hass	et	al.,	
2011).	 The	 “Linear	 discriminant	 analysis	 (LDA)	 effect	 size	 (LEfSe)”	
algorithm	was	 performed	 with	 the	 Galaxy	 online	 platform	 to	 de-
termine	the	different	relative	abundances	of	bacterial	communities	
among	the	different	groups	of	patients.	The	significance	thresholds	




2.7  |  Fecal calprotectin test
Fecal	calprotectin	(FC)	was	measured	as	a	marker	of	intestinal	inflam-
mation	by	using	 a	 commercial	 ELISA	 (MyBioSource),	 following	 the	
manufacturer's	instructions.	Optical	densities	were	read	at	405	nm	
with	a	microplate	ELISA	 reader.	Samples	were	 tested	 in	duplicate,	
and	results	were	calculated	from	a	standard	curve	and	expressed	as	
μg/g	stool	(Chang	&	Cheon,	2018).
2.8  |  Statistical analysis











were	performed	 to	 allow	pairwise	 comparison	of	microbiota	 from	





for	 Social	 Sciences	 SPSS	 v.18.0.	 was	 used,	 and	 p-	values	 of	 ≤0.05	
(2-	tailed)	were	considered	to	be	statistically	significant.
3  |  RESULTS
3.1  |  Study population
Eighteen	 patients	 diagnosed	 with	 UC	 and	 pancolitis,	 mean	 aged	
37-	years-	old	 constituted	 the	 study	 population,	 who	 were	 further	




tients	 with	 active	 pancolitis	 were	 characterized	 by	 being	 watery,	
corresponding	 to	 Bristol	 type	 7,	 and	 bloody	 (two	 points	 in	 rectal	
bleeding	of	Mayo	Clinical	Score)	in	all	cases.
3.2  |  Microbial composition and diversity
The	 analysis	 of	 microbiome	 from	 fecal	 samples	 showed	 the	 rela-
tive	 abundance	 of	OTUs	 at	 different	 taxonomic	 levels	 (Figure	 1a,	








similar	 to	 that	observed	 in	healthy	participants,	at	 the	phyla	 level;	
whereas,	active	pancolitis	showed	phylum	Proteobacteria	as	the	most	






and	Bacteroides	 (Appendix:	 Table	A1,	A2,	 and	A3).	Regarding	bac-
terial	alpha	diversity	comparison,	pancolitis	activity	was	related	to	
the	lowest	community	richness	(Chao	index)	and	diversity	(Shannon	









The	 structure	of	 the	most	 abundant	microbial	 species	was	ex-
plored	with	the	biomarker	of	UC	severity,	fecal	calprotectin;	where	
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the	clusters	of	the	different	phases	are	significantly	separated	based	
on	fecal	calprotectin	(Figure	3).
The	 microbial	 community	 structure	 was	 investigated	 by	 using	


















(n = 15) p- value
Age	(years	old) 36.9 ± 1.4 37.9	±	1.1 36. 4 ± 1.6 NS
Male 7	(77.7) 6	(66.6) 6	(40) NS
Index	CAI 11.0 ± 1.3 1.7	±	0.6 N/A <0.05
Montreal	A	(age	at	onset)



















≥	10 2 to 4 1 to 2 NS
Presence	of	blood	in	
stools
9	(100) None None NS
Time	(years)	from	diagnosis
≥10 8	(88.8) 6	(66.6) N/A NS
≤10 1	(11.1) 3	(33.3)
Currently	smoking 2	(22.2) None None N/A
Medication	use









TA B L E  1 Demographic	and	clinical	
characteristics	of	the	study	population	
(n	=	33)
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Phylum Firmicutes 4.0 ± 1.5*/** 50.0 ± 5.2 54.6 ± 6.4
Bacteroidetes 15.0 ± 0.2*/** 46.0 ± 4.2 45.0 ± 3.4
Proteobacteria 52.5 ± 5.6*/** 0.0 ± 0.0 2.5 ± 1.0
Fusobacteria 30.0 ± 2.5*/** 0.0 ± 0.0 0.0 ± 0.0
Actinobacteria 1.5 ± 0.5 2.5 ± 1.0 2.5 ± 1.0
Verrucomicrobia 0.0 ± 0.0 1.5 ± 0.3 1.5 ± 0.5
Genus Lactobacillus 0.0 ± 0.0*/** 5.6 ± 4.2 8.5 ± 2.4
Faecalibacterium 0.5 ± 1.5*/** 21.0 ± 8.7*** 40.2 ± 4.9
Roseburia 0.0 ± 0.0*/** 5.4 ± 7.2*** 7.3	±	7.4
Bacteroides 7.6	±	4.1 11.5 ± 10.8*** 3.5 ± 2.1
Bilophila 12.0 ± 9.1*/** 0.0 ± 0.0 0.0 ± 0.0





TA B L E  2 Comparison	of	gut	dysbiosis	
in	fecal	samples	from	the	pancolitis	
population
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Finally,	we	explored	whether	 the	 relative	abundance	of	 the	
bacterial	 genus	 most	 frequently	 observed	 (cutoff	 values	 ac-
cording	to	ROC	analysis:	active	vs.	remission	pancolitis	Bilophila 
10%,	 Faecalibacterium	 40%;	 pancolitis	 vs.	 healthy	 participants	




not	 for	 remission	pancolitis	vs.	healthy	participants	 (Appendix:	
Table	A6).






























of	 young	 aged	 patients	 with	 UC	 and	 severe	 stage	 of	 pancolitis.	
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Our	 results	 showed	 an	 increased	 proportion	 of	 the	 phylum	
Proteobacteria	 and	 the	 genera	 Fusobacterium	 and	 Bilophila	 in	 ac-
tive	pancolitis,	which	was	significantly	different	from	the	group	of	
remission	pancolitis	and	healthy	participants,	who	shared	a	micro-

















2018).	Consistently,	 reduced	 abundance	of	 these	microorganisms	
has	been	associated	with	a	higher	rate	of	recurrence	of	UC	(Alam	






Other	 findings	 were	 the	 higher	 abundance	 of	 the	 phylum	
Proteobacteria,	and	particularly	the	expansion	of	the	genus	Bilophila 
in	 active	 pancolitis.	 It	 is	 known	 that	 the	 relative	 abundance	 of	
Bilophila	 is	 promoted	 by	 diets	 enriched	 in	 saturated	 fats,	 which	
increase	 bacterial	 resistance	 to	 bile	 elimination.	 Furthermore,	
a	 change	 in	 the	 type	of	 fat	 consumed	affects	 the	 composition	of	
gut	microbiota,	 which	may	modify	 the	 onset	 and	 severity	 of	 UC	
(Devkota	 &	 Chang,	 2015;	 Pittayanon	 et	 al.,	 2020;	 Torres	 et	 al.,	
2018).	 Dietary	 modifications	 involving	 excessive	 consumption	 of	
fried	food,	dairy	products,	and	wheat	flour	are	associated	with	the	
development	of	 severe	diarrhea	 in	patients	with	 active	pancolitis	
(Keshteli	et	al.,	2019).	In	the	present	study,	we	consider	that	there	
is	no	 significant	effect	derived	 from	 the	modification	of	 the	diet,	
since	the	population	consumed	a	soft	diet	with	abundant	hydration;	
without	 a	 specific	 recommendation	 for	 dietary	 restrictions,	 even	
during	active	pancolitis.















scenarios	 studied.	 Remarkably,	 remission	 pancolitis	 and	 healthy	
participants	 showed	 the	 highest	 relative	 abundance	 of	 the	 phy-
lum	Firmicutes,	which	contributed	to	most	of	the	bacterial	diversity	
and	 richness	 (Björkqvist	 et	 al.,	 2019;	 Ganji-	Arjenaki	 &	 Rafieian-	
Kopaei,	2018;	Jandhyala	et	al.,	2015).	Further	analyses	of	cluster	
distribution	of	bacterial	communities	showed	differences	in	active	
pancolitis,	 as	 compared	 to	 remission	 pancolitis	 and	 healthy	 par-
















Finally,	 gut	 dysbiosis	 has	 been	proposed	 as	 an	 important	 con-




to	 selectively	 associate	with	 cases	 of	 activity/remission	 pancolitis	
(Fukuda	&	Fujita,	2014;	Guo	et	al.,	2019).
To	our	knowledge,	this	is	the	first	study	that	investigated	the	







that	 the	 analysis	 performed	 yields	 an	 adequate	 interpretation	
within	a	translational	context,	highlighting	the	role	of	microbiota	
diversity	 in	 the	clinical	phases	of	pancolitis.	Third,	 larger	 sample	
size	may	be	required	to	confirm	our	data	and	further	research	 is	
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differences	 in	 the	microbiota	 communities	 in	 patients	with	 active	
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APPENDIX 
TABLE	A1 List	of	bacterial	taxa	with	their	OTUs	ID	in	active	pancolitis
No. OTUs ID Bacteria No. OTUs ID Bacteria
1 925 Brenneria 49 471278 Buttiauxella
2 1006 Curtobacterium 50 479863 Shimwellia
3 1163 Microbacteriaceae 51 484145 Enterobacteriaceae
4 4981 Rothia 52 489853 Cronobacter
5 5294 Micrococcaceae 53 498961 Klebsiella
6 5605 Trueperella 54 501249 Enterobacteriaceae
7 6509 Actinomycetaceae 55 504890 Phocoenobacter
8 7967 Actinomyces 56 526378 Pasteurellaceae
9 8584 Actinomycetaceae 57 528975 Pasteurellaceae
10 9376 Anaerofilum 58 542569 Mannheimia
11 10096 Ruminococcaceae 59 554567 Actinobacillus
12 10256 Sporosarcina 60 561469 Aggregatibacter
13 10458 Planococcaceae 61 566893 Pasteurellaceae
14 10725 Gemella 62 576178 Haemophilus
15 11203 Bacillales 63 580361 Pasteurellaceae
16 14506 Pediococcus 64 603577 Fusobacteriaceae
17 14625 Lactobacillaceae 65 640658 Fusobacteriaceae
18 15213 Tetragenococcus 66 648973 Ilyobacter
19 16721 Enterococcaceae 67 689746 Propionigenium
20 19563 Delftia 68 704128 Fusobacteriaceae
21 125300 Comamonadaceae 69 728910 Bacteroides
22 128695 Burkholderiales 70 731897 Bacteroidaceae
23 132065 Neisseriaceae 71 735981 Blautia
24 136219 Rhodospirillum 72 765640 Lachnospiraceae
25 139865 Rhodospirillaceae 73 777038 Aeromonas
26 174563 Rhodospirillales 74 796328 Aeromonadaceae
27 176398 Gemmiger 75 857896 Coprococcus
28 182397 Hyphomicrobiaceae 76 871259 Lachnospiraceae
29 187569 Hyphomicrobiaceae 77 901257 Ruminococcaceae
30 195637 Rhizobiales 78 943078 Ruminococcus
31 198759 Campylobacterales 79 963365 Ruminococcaceae
32 201289 Campylobacter 80 1005973 Pseudomonas
33 206986 Campylobacteraceae 81 1019639 Pseudomonadaceae
34 217893 Campylobacterales 82 1025697 Enterococcus
35 241479 Pseudomonadales 83 1056986 Enterococcaceae
36 274893 Aeromonadaceae 84 1078963 Bacilli
37 289963 Shewanella 85 1086935 Escherichia
38 301329 Shewanellaceae 86 1087789 Fusobacterium
39 325698 Alteromonadales 87 1096348 Fusobacteriaceae
40 341449 Enterobacteriaceae 88 1098986 Fuobacteria
41 371893 Yersinia 89 1118963 Bilophila
42 378963 Providencia 90 1116035 Desulfovibrionaceae
43 390132 Pantoea 91 1131789 Desulfovibrionales
44 405698 Enterobacteriales 92 1135348 Deltaproteobacteria
45 424147 Citrobacter 93 1137986 Enterobacteriaceae
46 444893 Raoultella 94 1142963 Gammaproteobacteria
47 459993 Kluyvera 95 1145350 Enterobacteriaceae
48 461329 Enterobacteriaceae 96 1147789 Betaproteobacteria
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TABLE	A2 List	of	bacterial	taxa	with	their	OTUs	ID	in	remission	pancolitis
No. OTUs ID Bacteria No. OTUs ID Bacteria
1 9012 Peptococcus 49 502589 Pediococcus
2 9378 Trueperella 50 527810 Lactobacillus
3 9646 Actinomycetaceae 51 530182 Pilibacter
4 9899 Peptostreptococcaceae 52 537891 Enterococcaceae
5 10463 Dialister 53 540128 Lactobacillales
6 10896 Adlercreutzia 54 562189 Anaerococcus
7 11302 Bacteroides 55 567812 Peptoniphilus
8 14567 Bacteroidaceae 56 572143 Parvimonas
9 14996 Clostridiales 57 577810 Clostridiales
10 15027 Ruminococcaceae 58 583071 Pseudoramibacter
11 15201 Atopobium 59 594777 Eubacterium
12 16457 Lactobacillus 60 617802 Eubacteriaceae
13 16830 Collinsella 61 631492 Clostridiales
14 18473 Bradyrhizobium 62 637490 Peptococcus
15 18990 Rikenellaceae 63 658714 Peptococcaceae
16 117963 Clostridiaceae 64 669748 Acetanaerobacterium
17 118634 Bifidobacterium 65 689816 Ruminococcus
18 119012 Bifidobacteriaceae 66 705933 Butyricicoccus
19 119986 Peptostreptococcaceae 67 729801 Flavonifractor
20 122479 Catenibacterium 68 742137 Clostridium	IV
21 126239 Bacteroidales 69 775910 Ruminococcaceae
22 129301 Barnesiellaceae 70 778426 Parasporobacterium
23 134203 Erysipelotrichaceae 71 798763 Lachnospiraceae
24 137748 Prevotella 72 825479 Dorea
25 150193 Phascolarctobacterium 73 876900 Coprococcus
26 189760 Parabacteroides 74 889861 Lachnospiraceae
27 199127 Porphyromonas 75 918733 Ruminococcaceae
28 215079 Odoribacter 76 934759 Peptostreptococcus
29 215630 Butyricimonas 77 989744 Peptostreptococcaceae
30 217998 Barnesiella 78 1012989 Anaerostipes
31 260327 Porphyromonadaceae 79 1026597 Lachnospiraceae
32 269160 Prevotella 80 1044390 Pediococcus
33 285496 Prevotellaceae 81 1073619 Lactobacillaceae
34 290112 Alistipes 82 1079801 Enterococcus
35 301028 Rikenellaceae 83 1093607 Bacteroides
36 303241 Staphylococcus 84 1107218 Bacteroidaceae
37 339875 Staphylococcaceae 85 1128970 Bacteroidales
38 340178 Bacillales 86 1140126 Enterococcaceae
39 346920 Aerococcus 87 1149566 Clostridiales
40 375984 Aerococcaceae 88 1151490 Lachnospiraceae
41 379617 Granulicatella 89 1156301 Blautia
42 398863 Carnobacteriaceae 90 1189612 Ruminococcaceae
43 420159 Weissella 91 1211437 Roseburia
44 426713 Leuconostocaceae 92 1237019 Lachnospiraceae
45 456906 Enterococcaceae 93 1240789 Clostridiales
46 479802 Streptococcus 94 1246772 Faecalibacterium
47 481590 Streptococcaceae 95 1250116 Ruminococcaceae
48 499301 Lactobacillales 96 1257301 Clostridiales
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TABLE	A3 List	of	bacterial	taxa	with	their	OTUs	ID	in	healthy	participants
No. OTUs ID Bacteria No. OTUs ID Bacteria
1 11456 Rhodospirillum 49 583010 Dorea
2 11895 Duodenibacillus 50 588322 Roseburia
3 11634 Lactobacillales 51 593701 Lachnospiraceae
4 12581 Collinsella 52 601086 Faecalibacterium
5 12988 Atopobium 53 605865 Clostridiales
6 16217 Ruminococcaceae 54 612789 Bifidobacterium
7 18759 Bacteroidales 55 645277 Lachnospiraceae
8 24663 Enterococcus 56 648712 Blautia
9 169384 Leuconostocaceae 57 657899 Ruminococcaceae
10 183691 Bacteroidaceae 58 678970 Sutterella
11 183968 Enterococcaceae 59 698782 Rikenellaceae
12 214569 Streptococcus 60 719017 Prevotella
13 221447 Bacteroides 61 733265 Lactobacillales
14 225896 Streptococcaceae 62 739100 Staphylococcus
15 237562 Enterococcaceae 63 753101 Staphylococcaceae
16 268741 Porphyromonas 64 772368 Odoribacter
17 271458 Ruminococcaceae 65 794890 Porphyromonadaceae
18 276398 Phascolarctobacterium 66 827745 Eubacteriaceae
19 281145 Butyricimonas 67 875214 Eubacterium
20 287482 Parvimonas 68 889803 Clostridiales
21 301189 Pseudoramibacter 69 914732 Prevotella
22 308756 Clostridiales 70 963365 Prevotellaceae
23 324470 Peptococcus 71 980217 Butyricicoccus
24 328621 Peptococcaceae 72 998510 Ruminococcaceae
25 331398 Butyricicoccus 73 1038960 Clostridium
26 335563 Parabacteroides 74 1041517 Parasporobacterium
27 346308 Barnesiella 75 1048796 Dorea
28 362391 Flavonifractor 76 1057893 Lachnospiraceae
29 367522 Peptostreptococcus 77 1096780 Clostridiales
30 371145 Peptostreptococcaceae 78 1101203 Mobiluncus
31 376598 Acetanaerobacterium 79 1106891 Actinomyces
32 379856 Lachnospiraceae 80 1110289 Actinomycetaceae
33 392350 Pediococcus 81 1115981 Prevotella
34 398571 Anaerostipes 82 1145780 Dialister
35 402265 Enterococcus 83 1148765 Clostridiales
36 428796 Lactobacillaceae 84 1150127 Lachnospiraceae
37 441278 Ruminococcaceae 85 1159812 Bacteroides
38 449127 Ruminococcaceae 86 1163970 Bacteroidales
39 451281 Ruminococcus 87 1167095 Ruminococcus
40 456580 Clostridiaceae 88 1208976 Bacteroidaceae
41 459102 Bifidobacterium 89 1220178 Blautia
42 467458 Bifidobacteriaceae 90 1227141 Ruminococcaceae
43 481097 Peptostreptococcaceae 91 1240139 Roseburia
44 489810 Catenibacterium 92 1247890 Lachnospiraceae
45 501433 Bacteroidales 93 1261372 Faecalibacterium
46 510129 Bacteroides 94 1266716 Ruminococcaceae
47 514780 Barnesiellaceae 95 1284820 Clostridiales
48 568894 Erysipelotrichaceae 96 1289362 Clostridiales
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TABLE	A4 Diversity	Indexes	for	pancolitis	phases	and	healthy	participants
Diversity index HS AP RP p- value
Observed 7122.82 2321.01 4138.14 0.001
Chao1 4215.58 1112.32 3241.56 0.001
Shannon 4.1 1.0 3.6 0.001







p_Proteobacteria;c_Betaproteobacteria Active	Pancolitis 4.8999 0.042
p_Proteobacteria;c_Gammaproteobacteria Active	Pancolitis 4.8963 0.0210
p_Proteobacteria;c_Deltaproteobacteria;o_Desulfovibrionales Active	Pancolitis 4.8912 0.0160




p_Fusobacteria;c_Fusobacteria Active	Pancolitis 4.8569 0.0122
p_Fusobacteria;c_Fusobacteria;o_Fusobacteriales;f_Fusobacteriaceae Active	Pancolitis 4.8498 0.0132
p_Fusobacteria;c_Fusobacteria;o_Fusobacteriales;f_Fusobacteriaceae;g_Fusobacterium Active	Pancolitis 4.8475 0.0145
p_Firmicutes;c_Clostridia Remission	Pancolitis 4.8961 0.0394
p_Firmicutes;c_Clostridia;o_Clostridiales Remission	Pancolitis 4.8926 0.0058
p_Firmicutes;c_Clostridia;o_Clostridiales;f_Ruminococcaceae;g_Faecalibacterium Remission	Pancolitis 4.8912 0.0132
p_Firmicutes;c_Clostridia;o_Clostridiales;f_Lachnospiraceae Remission	Pancolitis 4.8859 0.0246
p_Firmicutes;c_Clostridia;o_Clostridiales;f_Lachnospiraceae;g_Roseburia Remission	Pancolitis 4.6898 0.0322
p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_Bacteroidaceae Remission	Pancolitis 4.6889 0.0125
p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales Remission	Pancolitis 4.6885 0.0203
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TABLE	A6 Diagnostic	performance	of	Bilophila,	Fusobacterium,	Faecalibacterium,	and	Roseburia	in	discriminating	Pancolitis-	related	
conditions
AUC Se (%) Sp (%) PPV (%) NPV (%)
AP	vs.	HS
Bilophila 0.917 80 100 100 83
Fusobacterium 0.955 90 100 100 90
Faecalibacterium 0.222 0 80 0 44
Roseburia 0.237 0 90 0 47
AP	vs.	RP
Bilophila 0.917 80 100 100 83
Fusobacterium 0.955 90 100 100 90
Faecalibacterium 0.206 10 10 10 10
Roseburia 0.237 0 90 0 47
RP	vs.	HS
Bilophila 0.000 N/A 100 N/A 50
Fusobacterium 0.000 N/A 100 N/A 50
Faecalibacterium 0.237 90 0 47 0
Roseburia 0.400 40 60 50 50
Cutoffs.	HS	vs.	AP	discrimination:	Bilophila	(10%),	Fusobacterium	(10%),	Faecalibacterium	(45%),	Roseburia	(20%).	AP	vs	RP	discrimination:	Bilophila	
(10%),	Faecalibacterium	(40%),	Roseburia	(20%).	HS	vs	RP	discrimination:	Bilophila	(5%),	Fusobacterium	(5%),	Faecalibacterium	(20%),	Roseburia	
(10%).
Abbreviatures:	AP,	Active	Pancolitis;	AUC,	Area	Under	the	Curve;	HS,	Healthy	Subjects;	N/A,	non-	applicable;	NPV,	Negative	Predictive	Value;	PPV,	
Positive	Predictive	Value;	RP,	Remission	Pancolitis;	Se,	Sensitivity;	Sp,	Specificity.	Bold	letters	and	values	indicates	the	most	abundant	and	have	
statistical	significance.
